

### **Hybrigenics Services signs a master agreement with L'Oreal**

#### **Hybrigenics Services will perform comprehensive protein interactions studies beyond classical Yeast Two-Hybrid technology**

**Paris, 14 September 2010** – Hybrigenics SA (ALHYG), a bio-pharmaceutical company listed on Alternext (NYSE-Euronext) in Paris, with a focus on research and development of new cancer treatments and specialised in protein interactions, today announces the signature of an open-ended master agreement between its fully-owned subsidiary, Hybrigenics Services SAS, and L'Oreal. The objective of this contract is to increase the volume, range and scope of protein interactions studies that Hybrigenics has been performing for L'Oreal in the past six years. The first orders under this agreement amount to €390,000 for the second half of 2010.

*"The world leader in the cosmetics industry, L'Oréal, has once again placed its trust in Hybrigenics' functional proteomics expertise and plans to use the full range of technologies offered by Hybrigenics Services",* said Etienne Formstecher, Hybrigenics Services' Head of Marketing, Sales & Project Management. *"This master agreement is an example of how Hybrigenics is designing its service activities to foster future revenue growth",* added Remi Delansorne, Hybrigenics SA' s CEO.

#### **About Hybrigenics**

Hybrigenics SA ([www.hybrigenics.com](http://www.hybrigenics.com)) is a bio-pharmaceutical company listed (ALHYG) on Alternext (NYSE-Euronext) in Paris, focusing its internal R&D programs on innovative targets and therapies for the treatment of cancer. Hybrigenics SA' development program is based on inecalcitol, a vitamin D analogue, for the treatment of hormone-refractory prostate cancer in combination with Sanofi-Aventis' Taxotere<sup>®</sup>, which is the current gold-standard chemotherapeutic treatment for this indication. Hybrigenics' research program explores the role of enzymes known as ubiquitin-specific proteases (USP) in the degradation of onco-proteins, and the effectiveness of proprietary USP inhibitors in treating various types of cancer.

Hybrigenics Services SAS is the market leader in Yeast Two-Hybrid (Y2H) and related services to identify, validate and inhibit protein interactions for researchers in all areas of life sciences, using its ISO 9001-certified high-throughput Y2H screening platform, its sophisticated bioinformatics tools and extensive database, along with its chemical library and chemical screening platform. Hybrigenics Services can also perform simple Yeast One-Hybrid (Y1H), membrane Y2H and chemical Yeast Three-Hybrid (Y3H) screens; homogeneous time-resolved fluorescence (HTRF<sup>®</sup>) and surface plasmon resonance (SPR) are additional technologies to characterize and analyze protein interactions offered by Hybrigenics Services.

\*\*\*

# HYBRIGENICS

Press Release

**HYBRIGENICS is listed on the Alternext by NYSE Euronext Paris**

**ISIN: FR0004153930**

**Ticker: ALHYG**



**Hybrigenics**  
Rémi Delansorne  
CEO  
Tel.: +33 (0)1 58 10 38 00  
investors@hybrigenics.com

**NewCap.**  
Financial communication  
Axelle Vuillermet / Pierre Laurent  
Tel.: +33 (0)1 44 71 94 94  
hybrigenics@newcap.fr